Ivacaftor for Cystic Fibrosis

Recent FDA approval of Ivacaftor (Kalydeco) is a promising step for a subset of patients with cystic fibrosis who have the G551D mutation.  This drug enhances the cystic fibrosis transmembrane regulator (CFTR) gene in these patients; only ~4% of CF patients or about 1200 patients in the US have this genetic defect.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm

Additional references:

-NEJM 2011; 365: 1663. Effect of VX-770 -a CFTR potentiator -mild improvement in study of 167 pts. (Ivacaftor).
-NEJM 2010; 363: 1991. Effect of VX-770 -a CFTR potentiator -mild improvement in study of 39 adults.

5 thoughts on “Ivacaftor for Cystic Fibrosis

  1. Pingback: Breaking down lung defenses in Cystic Fibrosis | gutsandgrowth

  2. Pingback: Gastrostomy Tubes for Children with Cystic Fibrosis | gutsandgrowth

  3. Pingback: Progress in Cystic Fibrosis over 18 Years | gutsandgrowth

  4. Pingback: “Origins of Cystic Fibrosis Lung Disease” | gutsandgrowth

  5. Pingback: Lumacaftor-Ivacaftor for Cystic Fibrosis | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.